Levine Leichtman Capital Partners invests in SEV Laser

UNITED STATES Health Providers / Outpatient Care / Aesthetic & Cosmetic Clinics EV $300–700M

Context

Structured as a structured private equity partnership, this investment by Levine Leichtman Capital Partners secures a platform investment in SEV alongside founder and Chief Executive Officer Sevana Petrosian. Announced in Los Angeles on June 21, 2023, the transaction establishes SEV as the tenth platform investment completed through the investment vehicle Levine Leichtman Capital Partners VI, L.P. Corporate governance under the recapitalized structure maintains operational leadership continuity with Sevana Petrosian and the existing executive and clinical management teams directing daily branch operations. The transaction establishes an institutional foundation to finance SEV's territorial multi-unit expansion through greenfield office openings, same-store sales acceleration, and the rollout of new aesthetic service lines across target regional markets. The partnership aligns with Levine Leichtman Capital Partners' investment mandate targeting multi-unit consumer healthcare concepts and service models. To execute the transaction, Levine Leichtman Capital Partners mandated Kirkland & Ellis LLP and Polsinelli LLP to serve as legal counsel. Sell-side advisory execution was coordinated exclusively by investment bank North Point, which acted as the exclusive financial advisor to SEV, while legal representation for SEV was managed by Buchalter, a Professional Corporation.

SEV Laser, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2010 in Burbank, California, by Sevana Petrosian, SEV functions as a manager and operator of medical spas specializing in aesthetic clinical treatments. The company's service portfolio centers on delivering laser hair removal, cosmetic injectables, body contouring, and advanced medical aesthetic procedures directly to consumers at an accessible price point. Operational oversight is coordinated under the ongoing leadership of founder and Chief Executive Officer Sevana Petrosian alongside dedicated in-house clinical teams. From an infrastructure standpoint, the aesthetic healthcare platform operates and manages a network of 27 clinical offices distributed across seven states. The operating format relies on standardized medical protocol execution and specialized aesthetic equipment deployed within retail-oriented clinical settings to address client demands for non-invasive cosmetic dermatology treatments.

Ent. Value

$300–700M

Equity Value

[members only]

Multiples

EV / Revenue

4x–10x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with Levine Leichtman Capital Partners

Other operations with Levine Leichtman Capital Partners
Date	Acquirer	Target	Country	Sector
08/2026	LEVINE LEICHTMAN CAPITAL PARTNERS	COLT GROUP	UNITED STATES	Welding & Piping Services
02/2024	LEVINE LEICHTMAN CAPITAL PARTNERS	USA WATER	UNITED STATES	Water

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
08/2023	BAIN CAPITAL	ESTIA HEALTH	AUSTRALIA	Nursing Homes
07/2023	MEDIAN KLINIKEN	HESTIA ALLIANCE	SPAIN	Clinics / Hospitals
06/2023	ARDIAN	MON VETO	FRANCE	Vet Clinics
06/2023	PARQUEST CAPITAL	IMANEO	FRANCE	Radiology
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Radiology
10/2022	CBPE CAPITAL	VEINCENTRE	UNITED KINGDOM	Aesthetic & Cosmetic Clinics
09/2022	EURAZEO	IMAPOLE	FRANCE	Radiology
09/2022	ORADIANSE	REVEL	FRANCE	Radiology
08/2022	FREEMAN SPOGLI	EVERVET PARTNERS	UNITED STATES	Vet Clinics
07/2022	ANDERA PARTNERS	GROUPE RESONANCE IMAGERIE	FRANCE	Radiology

REFERENCES

Valuation range: EV $300–700M

Revenue range: $25–50M

EBITDA range: $5–25M

EV/Revenue range: 4x - 10x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SEV Laser by Levine Leichtman Capital Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: sev laser

FAQ

What transaction does this page cover?

This page covers the acquisition of a minority stake in SEV Laser, an American company specialised in Outpatient Care, by Levine Leichtman Capital Partners in 2023, structured as a leveraged buyout (LBO).

How was the acquisition of SEV Laser by Levine Leichtman Capital Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $300–700M band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 4x - 10x range. Exact figures are available to members.

What were SEV Laser’s revenue and EBITDA at the time of the deal?

At the time of the transaction, SEV Laser generated annual revenue estimated in the $25–50M range and EBITDA in the $5–25M bracket (FY 2023). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.